UAB Digital Repository of Documents 23 records found  1 - 10nextend  jump to record: Search took 0.00 seconds. 
1.
15 p, 3.7 MB Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance / Botta, Cirino (Clinica Universidad de Navarra) ; Perez, Cristina (Clinica Universidad de Navarra) ; Larrayoz, Marta (Clinica Universidad de Navarra) ; Puig, Noemí (Hospital Universitario de Salamanca) ; Cedena, María Teresa (Hospital Universitario 12 de Octubre) ; Termini, Rosalinda (Clinica Universidad de Navarra) ; Goicoechea, Ibai (Clinica Universidad de Navarra) ; Rodriguez, Sara (Clinica Universidad de Navarra) ; Zabaleta, Aintzane (Clinica Universidad de Navarra) ; Lopez, Aitziber (Clinica Universidad de Navarra) ; Sarvide, Sarai (Clinica Universidad de Navarra) ; Blanco, Laura (Clinica Universidad de Navarra) ; Papetti, Daniele Marco (Department of Informatics. University of Milano-Bicocca) ; Nobile, M.S. (Biostatistics and Bioimaging Centre-B4) ; Besozzi, Daniela (Biostatistics and Bioimaging Centre-B4) ; Gentile, Massimo (Department of Oncohematology. "Annunziata" Hospital) ; Correale, Pierpaolo (Great Metropolitan Hospital "Riuniti" of Reggio Calabria) ; Siragusa, Sergio (Department of Health Promotion. University of Palermo) ; Oriol, Albert (Institut Català d'Oncologia i Institut Josep Carreras) ; González-Garcia, Maria Esther (Hospital de Cabueñes) ; Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; de Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ; Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Moraleda, José María (Instituto Murciano de Investigación Biosanitaria) ; Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ; Hernández, Miguel T. (Hospital Universitario de Canarias (Illes Canàries)) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Illes Balears)) ; Palomera, Luís (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Pérez-Montaña, Albert (Hospital Universitari Son Espases (Illes Balears)) ; Goldschmidt, Hartmut (Department of Internal Medicine V. University of Heidelberg) ; Avet-Loiseau, Hervé (IUC-T Oncopole) ; Roccaro, Aldo (Department of Hematology. ASST Spedali Civili di Brescia) ; Orfao, Alberto (Department of Medicine. University of Salamanca) ; Martinez-Lopez, Joaquín (Hospital Universitario 12 de Octubre) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Lahuerta, J. J (Hospital Universitario 12 de Octubre) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Mateos, M. V (Hospital Universitario de SalamancaBiomedica de Salamanca (IBSAL). Centro de Investigación del Cancer (IBMCC-USAL. CSIC)) ; San-Miguel, J (Clinica Universidad de Navarra) ; Martinez Climent, Juan-José (Clinica Universidad de Navarra) ; Paiva, Bruno (Clinica Universidad de Navarra)
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). [...]
2023 - 10.1038/s41467-023-41562-6
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 5825  
2.
10 p, 496.7 KB Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis / Facon, Thierry (Lille University Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital, South Korea) ; Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ; Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Yağci, Münci (Gazi University, Ankara, Turkey) ; Cavo, Michele (Bologna University School of Medicine, Italy) ; Yong, Kwee (University College Hospital, London, UK) ; Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ; Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ; Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ; Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 - 10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029  
3.
10 p, 3.0 MB Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era / Salas, María Queralt (Hospital Clínic i Provincial de Barcelona) ; Rodríguez Lobato, Luis Gerardo (Hospital Clínic i Provincial de Barcelona) ; Charry, Paola (Hospital Clínic i Provincial de Barcelona) ; Suárez-Lledó, Maria (Hospital Clínic i Provincial de Barcelona) ; Pedraza, Alexandra (Hospital Clínic i Provincial de Barcelona) ; Solano, María Teresa (Hospital Clínic i Provincial de Barcelona) ; Arcarons, Jordi (Hospital Clínic i Provincial de Barcelona) ; Cid, Joan (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Lozano, Miquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Esteve, Jordi (Hospital Clínic i Provincial de Barcelona) ; Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fernandez Aviles, Francesc (Hospital Clínic i Provincial de Barcelona) ; Martínez, Carmen (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised Pre-Transplantation Assessment of Mortality (rPAM) Scores and Endothelial Activation and Stress Index (EASIX)] in 205 adults undergoing post-transplant cyclophosphamide (PTCy)-based allo-HCT. [...]
2023 - 10.1016/j.htct.2023.07.008
Hematology, Transfusion and Cell Therapy, 2023  
4.
12 p, 1.6 MB Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma / Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Hebraud, Benjamin (Institut Universitaire du Cancer de Toulouse-Oncopole) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Colin, Anne-Laurène (Ser Centre Hospitalier et Universitaire de Toulouse) ; Ríos Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Hulin, Cyrille (Department of Hematology. Hôpital Haut-Lévêque) ; Blanchard, María Jesús (Hospital Ramón y Cajal) ; Caillot, Denis (Hôpital du Bocage) ; Sureda, Anna (Universitat de Barcelona) ; Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ; Arnulf, Bertrand (Hôpital St-Louis) ; Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ; Macro, Margaret (Centre Hospitalier et Universitaire de Caen) ; San-Miguel, J (Clínica Universidad de Navarra) ; Belhadj, Karim (Centre Hospitalier et Universitaire Henri Mondor) ; Lahuerta, J. J (Clínica Universidad de Navarra) ; Garelik, M.Brigid (Bristol-Myers Squibb Company) ; Bladé, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Objective: Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM. [...]
2023 - 10.3389/fonc.2023.1197340
Frontiers in Oncology, Vol. 13 (2023) , p. 1197340  
5.
8 p, 1.0 MB Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma / Moreau, Philippe (University Hospital Hôtel-Dieu) ; Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ; Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K (Winship Cancer Institute. Emory University) ; Martin, Thomas (University of California San Francisco) ; Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ; Karlin, Lionel (Centre Hospitalier Lyon Sud) ; Benboubker, Lotfi (Hôpital Bretonneau) ; Mateos, Maria-Victoria (University Hospital de Salamanca) ; Popat, Rakesh (University College London Hospitals) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Sidana, Surbhi (Stanford University of Medicine) ; Delforge, Michele (University of Leuven) ; Pei, Lixia (Janssen Research & Development) ; Trancucci, Danielle (Janssen Research & Development) ; Olyslager, Yunsi (Janssen Research & Development) ; Uhlar, Clarissa (Janssen Research & Development) ; Stephenson, Tara (Janssen Research & Development) ; Rampelbergh, Rian Van (Janssen Research & Development) ; Banerjee, Arnob (Janssen Research & Development) ; Kobos, Rachel (Janssen Research & Development) ; Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818  
6.
9 p, 1.0 MB Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain : The CharisMMa Study / Ocio, Enrique M. (Instituto de Investigación Sanitaria Valdecilla (Cantàbria)) ; Montes-Gaisán, Carmen (Instituto de Investigación Sanitaria Valdecilla (Cantàbria)) ; Bustamante, Gabriel (Institut Català d'Oncologia) ; Garzón, Sebastián (Hospital de Jerez) ; González, Esther (Hospital Universitario de Cabueñes (Gijón)) ; Pérez Persona, Ernesto (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ; Sirvent, Maialen (Hospital de Donostia (País Basc)) ; Arguiñano, José María (Complejo Hospitalario Navarra) ; González, Yolanda (Institut Català d'Oconologia) ; Ríos-Tamayo, Rafael (Hospital Virgen de las Nieves (Andalusia)) ; de Miguel, Dunia de (Hospital Universitario de Guadalajara) ; Grande, Marta (Universidad de Alcalá) ; Fernández, Alfonso (Takeda Farmacéutica España) ; Naves, Andrea (Takeda Farmacéutica España) ; Rosiñol, Laura (Universitat de Barcelona)
Introduction: Treatment of relapsed and/or refractory multiple myeloma (RRMM) should be established based on multiple factors, including previous treatment and the sociodemographic/clinical characteristics of the patients. [...]
2022 - 10.1016/j.clml.2021.10.001
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 4 (april 2022) , p. e241-e249  
7.
9 p, 603.3 KB Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study / Martin, Thomas G. (University of California San Francisco, USA) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ; Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ; Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ; Mateos, María Victoria (Hospital Universitario de Salamanca) ; San-Miguel, Jesús F. (Clínica Universidad de Navarra) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K. (Emory University, Atlanta, GA) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ; Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ; Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Bahlis, Nizar (University of Calgary, Canada) ; Popat, Rakesh (University College London) ; Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ; Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ; Pei, Lixia (Janssen Research & Development, Raritan, NJ) ; Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ; Fastenau, John (Janssen Research & Development, Raritan, NJ) ; Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ; van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023  
8.
4 p, 756.5 KB Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS / Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Haenel, M. (Klinikum Chemnitz, Germany) ; Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ; Ailawadhi, Sikander (Mayo Clinic Florida, USA) ; Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ; de la Rubia Comos, Javier (Catholic University of Valencia) ; Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ; Mateos, M. V (Hospital Universitario de Salamanca) ; Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ; Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ; Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ; Terebelo, Howard (Providence Cancer Center, Southfield, USA) ; Yang, Shiyi (Janssen Research & Development. LLC, USA) ; Wang, Jianping (Janssen Research & Development. LLC, USA) ; Nnane, Ivo (Janssen Research & Development. LLC, USA) ; Qi, Ming (Janssen Research & Development. LLC, USA) ; Kosh, Michele (Janssen Research & Development. LLC, USA) ; Delioukina, Maria (Janssen Research & Development. LLC, USA) ; Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)  
9.
14 p, 1.7 MB Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials / López-Anglada, Lucía (Hospital 12 de Octubre (Madrid)) ; Cueto-Felgueroso, Cecilia (Hospital 12 de Octubre (Madrid)) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Teruel, Ana Isabel (Hospital Clínic Universitari (València)) ; Lopez de la Guia, Ana (Hospital Universitario La Paz (Madrid)) ; Bengoechea, Enrique (Hospital de Donostia (Sant Sebastià, País Basc)) ; Palomera, Luis (Hospital Clínico Universitario Lozano Blesa) ; De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ; Hernandez, Jose Mariano (Hospital General de Segovia) ; Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Peñalver, Francisco Javier (Hospital Universitario Fundacion Alcorcon) ; García-Sanz, Ramón (Hospital Universitario de Salamanca-IBSAL) ; Besalduch, Juan (Hospital Univarsitari Son Espases) ; Gonzalez Montes, Yolanda (Institutd'Oncologia Dr Josep Trueta de Girona) ; Martinez, Rafael Benigno (Hospital Universitario Clínico San Carlos (Madrid)) ; Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ; Gutierrez, Norma C. (Hospital Clínic i Provincial de Barcelona) ; Puerta, Paloma (Hospital 12 de Octubre (Madrid)) ; Valeri, Antonio (Hospital 12 de Octubre (Madrid)) ; Paiva, Bruno (Clínica Universidad de Navarra) ; Bladé Creixenti, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mateos, Maria-Victoria (Hospital Clínic i Provincial de Barcelona) ; San-Miguel, J (Clínica Universidad de Navarra) ; Lahuerta, J. J. (Hospital Universitario 12 de Octubre (Madrid)) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. [...]
2018 - 10.1371/journal.pone.0203392
PloS one, Vol. 13 Núm. 9 (september 2018) , p. e0203392  
10.
8 p, 1.1 MB A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma / Encinas, Cristina (Hospital General Universitario Gregorio Marañón (HGUGM). IiSGM) ; Hernandez-Rivas, José-Ángel (Hospital Universitario Infanta Leonor) ; Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona. CIBERONC) ; Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ; Bellón, José-María (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; García-Sanz, Ramón (Hospital Universitario de Salamanca (IBSAL). CIBERONC e Instituto de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC)) ; de la Rubia, Javier (Hospital Universitari Doctor Peset (València)) ; López de la Guía, Ana (Hospital Universitario La Paz (Madrid)) ; Jímenez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ; Jarque, Isidro (Hospital Universitario la Fe. CIBERONC) ; Iñigo, Belén (Hospital Clínico San Carlos (Madrid)) ; Dourdil, Victoria (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; De Arriba, Felipe (Hospital J.M. Morales Meseguer) ; Cuéllar Pérez-Ávila, Clara (Hospital Universitario 12 de Octubre (Madrid)) ; Gonzalez, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta) ; Hernández, Miguel-Teodoro (Hospital Universitario de Canarias (La Laguna)) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Rodríguez-Otero, Paula (Clínica Universitaria de Navarra. CIMA. IDISNA. CIBERONC) ; Silvent, Maialen (Hospital de Donostia (Sant Sebastià, País Basc)) ; Cabrera, Carmen (Complejo Hospitalario de Cáceres) ; Rios, Rafael (Hospital Universitario Virgen de las Nieves (Granada)) ; Alegre, Adrián (Hospital Universitario de la Princesa. Hospital Universitario Quirónsalud) ; Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ; Gonzalez, Marta-Sonia (Hospital Universitario de Santiago) ; Sureda, Anna (Institut Català d'Oncologia) ; Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Ocio, Enrique M. (Hospital Universitario Marqués de Valdecilla. (IDIVAL). Universidad de Cantabria) ; Krsnik, Isabel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; García, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; García-Mateo, Aránzazu (Hospital General de Segovia) ; Soler, Joan-Alfons (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Martín Sánchez, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Arguiñano, José M (Complejo Hospitalario de Navarra) ; Mateos, M. V. (Instituto de Investigación Biomédica de Salamanca) ; Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona. CIBERONC) ; San-Miguel, J (Clínica Universitaria de Navarra. CIMA. IDISNA; CIBERONC) ; Lahuerta, J. J (Hospital Universitario 12 de Octubre (Madrid)) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. [...]
2022 - 10.1038/s41408-022-00652-2
Blood Cancer Journal, Vol. 12 Núm. 4 (april 2022) , p. 68  

UAB Digital Repository of Documents : 23 records found   1 - 10nextend  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.